PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
Latest Information Update: 16 Dec 2024
Price :
$35 *
At a glance
- Drugs Piflufolastat F18 (Primary)
- Indications Prostate cancer
- Focus Biomarker; Diagnostic use
- 12 Dec 2024 Status changed from recruiting to completed.
- 22 Aug 2024 Planned number of patients changed from 104 to 136.
- 22 Aug 2024 Planned End Date changed from 1 Dec 2024 to 31 Dec 2024.